These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38133189)

  • 1. The Effect of OnabotulinumtoxinA on Headache Intensity and Number of Monthly Headache Days in Individuals with Chronic Migraine with Different Levels of Neck Disability.
    Onan D; Arıkan H; Martelletti P
    Toxins (Basel); 2023 Dec; 15(12):. PubMed ID: 38133189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity.
    Onan D; Bentivegna E; Martelletti P
    Toxins (Basel); 2022 Dec; 15(1):. PubMed ID: 36668849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.
    Silberstein SD; Diener HC; Dodick DW; Sommer K; Lipton RB
    Headache; 2024; 64(7):838-848. PubMed ID: 38982666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
    Santoro A; Fontana A; Miscio AM; Zarrelli MM; Copetti M; Leone MA
    Neurol Sci; 2017 Oct; 38(10):1779-1789. PubMed ID: 28726049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
    J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.
    Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Makris N; Kararizou E
    J Headache Pain; 2018 Sep; 19(1):87. PubMed ID: 30225735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
    Mathew NT; Jaffri SF
    Headache; 2009; 49(10):1466-78. PubMed ID: 19912346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
    J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
    Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
    J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
    Dodick DW; Silberstein SD; Lipton RB; DeGryse RE; Adams AM; Diener HC
    Cephalalgia; 2019 Jul; 39(8):945-956. PubMed ID: 31112399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy.
    Santoro A; Copetti M; Miscio AM; Leone MA; Fontana A
    Neurol Sci; 2020 Jul; 41(7):1809-1820. PubMed ID: 32052306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Jan; 20(1):10. PubMed ID: 30669961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C; Stark R; Limberg N; Rodrigues J; Cordato D; Schwartz R; Jukic R
    J Headache Pain; 2019 Jul; 20(1):81. PubMed ID: 31307383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
    Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU
    Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.
    Khalil M; Zafar HW; Quarshie V; Ahmed F
    J Headache Pain; 2014 Sep; 15(1):54. PubMed ID: 25178393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.